Hematopoietic and multipotent mesenchymal stromal cell co-transplantation in oncohematological diseases increases the risk of recurrence

A. S. Grigoryan

doi:10.23868/gc156509

Genes & Cells ›› 2008, Vol. 3 ›› Issue (2) : 23 -25. DOI: 10.23868/gc156509

Clinical researches

research-article

Hematopoietic and multipotent mesenchymal stromal cell co-transplantation in oncohematological diseases increases the risk of recurrence

A. S. Grigoryan

Author information +

History +

PDF

Abstract

Cite this article

Download citation ▾

A. S. Grigoryan. Hematopoietic and multipotent mesenchymal stromal cell co-transplantation in oncohematological diseases increases the risk of recurrence. Genes & Cells, 2008, 3(2): 23-25 DOI:10.23868/gc156509

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Armitage J.O. Bone marrowtransplantation.N. Engl. J. Med. 1994; 330: 827-38.

[2]	Yeager A.M. Allogeneic hematopoietic cell transplantation in inborn metabolic diseases. Ann. Hematol. 2002; 81:16-9.

[3]	Burt R.K., Traynor A.E., Craig R., Marmont A.M. The promise of hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant. 2003; 31:521-4.

[4]	Wingard J.R., Vogelsang G.B., Deeg H.J. Stem cell transplantation: supportive care and long-term complications. Hematology 2002, 422-44.

[5]	Tabbara I.A., Zimmerman K., Morgan C., Nahleh Z. Allogeneic hematopoietic stem cell transplantation: complications and results. Arch. Intern. Med. 2002;162:1558-66.

[6]	Antin J.H., Chen A.R., Couriel D.R. et al. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol. Blood Marrow Transplant. 2004; 10: 655-68.

[7]	Ferrara J.L., Deeg H.J.. Graft-versus-host disease. N. Engl. J. Med. 1991; 324: 667-74.

[8]	Marmont A.M., Horowitz M.M., Gale R.P. et al. Depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-30.

[9]	Pittenger M.F., Mackay A.M., Beck S.C. et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143-7.

[10]	Koc O.N., Gerson S.L., Cooper B.W. et al. Rapid hematopoietic recovery after co-infusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J. Clin. Oncol. 2000; 18: 307-16.

[11]	Bartholomew A., Sturgeon C., Siatskas M. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002; 30: 42-8.

[12]	Krampera M., Glennie S., Dyson J. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-9.

[13]	Tse W.T., Pendleton J.D., Beyer W.M. et al. Suppression of allogeneic T-cell proliferation by human marrow Leukemia stromal cells: implications in transplantation. Transplantation 2003; 75: 389-97.

[14]

Frassoni F., Labopin M., Bacigalupo A. et al. Expanded mesenchymal stem cells (MSC), coinfused with HLA identical hematopoietic stem cells transplants, reduce acute and chronic graft-versus-host disease: a matched pair analysis in hematologic malignancy patients. Bone Marrow Transplant. 2002; 29 [suppl 2): S2 [Abstract 75].

[15]	Le Blanc K., Rasmussen I., Sundberg B. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-41.

[16]	Djouad F., Plence P., Bony C. et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837-44.